血管扩张药物和系统性硬化症中与心脏相关的结果:探索性分析
Alexis F Guédon1,2, Fabrice Carrat3, Luc Mouthon4
1Institut Pierre Louis d'Epidemiologie et de Sante Publique, Paris, Île-de-France, France alexis.guedon2@aphp.fr.
RMD open
|December 10, 2024
概括
系统性硬化症患者可能会从心脏问题中受益于西尔代纳菲尔. 这项研究发现,西尔德纳菲尔改善了SSc患者的腹功能障碍和射出分数,与其他血管扩张剂不同.
科学领域:
- 心脏病学 心脏病学
- 类风湿病学 类风湿病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 系统性硬化症 (SSc) 是一种自身免疫性疾病,导致纤维化和心脏问题,是导致死亡的主要原因.
- 在SSc中心脏表现显著影响患者的治疗结果和生存率.
- 评估各种血管扩张治疗的疗效对于管理SSc相关的心脏并发症至关重要.
研究的目的:
- 评估西尔代纳菲尔,博森坦,ACE抑制剂和伊洛普罗斯特对SSc患者心脏功能的影响.
- 为了确定治疗对扩张功能障碍,减排分数和肺动脉高血压 (PAH) 的平均治疗效果 (ATE).
- 利用因果推理方法,对混因素和信息审查进行强有力的调整.
主要方法:
- 来自法国SSc数据库的国家多中心前性研究数据的分析.
- 应用纵向目标最小损失估计 (TMLE) 进行因果效应估计.
- 包括1048名SSc患者,可供分析的治疗数据.
主要成果:
- 三年后,西尔德纳菲尔显示出显著的ATE在减少腹功能障碍 (-2.83%) 和改变射出分数 (<50%) (-0.88%) 中.
- 在肺动脉高血压 (PAH) 上没有观察到西尔代纳菲尔对肺动脉高血压 (PAH) 的显著影响.
- 博森坦,ACE抑制剂和伊洛普罗斯特对透缩功能障碍,改变射出分数或PAH没有显著影响.
结论:
- 这项研究表明,在SSc患者中,西尔德纳菲尔可能对腹功能障碍和改变的射出分数有好处.
- 这些发现突出了西尔代纳菲尔作为SSc.特定心脏表现的潜在治疗选择.
- 需要进一步的研究来证实这些探索性发现,并评估SSc中血管扩展剂的长期心脏相关结果.
相关概念视频
01:23Antihypertensive Drugs: Vasodilators
476
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
476
01:22Heart Failure Drugs: β-Blockers
316
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
316
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
385
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
385
01:18Cardiovascular Drugs: Classification based on Therapeutic Indications
2.0K
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
2.0K
01:20Vascular Resistance
3.4K
Vascular resistance is a critical concept in understanding blood flow dynamics in the circulatory system. It refers to the resistance that blood encounters as it flows through the blood vessels. This resistance is a key factor in determining blood pressure and cardiac workload.
The primary determinants of vascular resistance are vessel diameter, blood viscosity, and vessel length. Among these, vessel diameter plays the most significant role due to the fourth power relationship described by...
The primary determinants of vascular resistance are vessel diameter, blood viscosity, and vessel length. Among these, vessel diameter plays the most significant role due to the fourth power relationship described by...
3.4K